Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 60
Filtrar
1.
Korean Journal of Medicine ; : 303-307, 2017.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-189027

RESUMO

Actinomycosis is a rare chronic suppurative infectious disease caused by Actinomyces spp. Actinomyces are anaerobic Gram-positive bacteria that colonize the mouth, digestive tract, and genital tract. Thoracic actinomycosis is caused by the aspiration of oropharyngeal materials or the spread of cervicofacial infections. Therefore, poor oral hygiene, smoking, and immunodeficiency are risk factors. Actinomycoses are frequently misdiagnosed as anatomical malignancies and thus assessments of the diseases underlying malignancies are often complicated by the presence of actinomycoses. Here, we report a case of mediastinal actinomycosis presenting with clinical and radiological features of metastatic pancreatic cancer. Clinicians should consider the presence of actinomycosis when cancer patients fail to respond to anti-cancer treatments.


Assuntos
Humanos , Actinomyces , Actinomicose , Colo , Doenças Transmissíveis , Trato Gastrointestinal , Bactérias Gram-Positivas , Linfonodos , Boca , Metástase Neoplásica , Higiene Bucal , Neoplasias Pancreáticas , Fatores de Risco , Fumaça , Fumar
4.
Korean Journal of Medicine ; : 353-357, 2015.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-216641

RESUMO

Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a rare subtype of malignant non-Hodgkin lymphoma, in which 40% of the cases show spontaneous regression without aggressive treatment. Surgery and focal radiation therapy are the primary forms of treatment for this disease; however, if pcALCL is accompanied by multifocal skin lesions, chemotherapy is also common. The prognosis for pcALCL is generally excellent, with a 5-year survival rate of 85-100%. However, pcALCL with extensive limb disease typically has a poor prognosis. Here, we present a case of pcALCL with extensive limb disease that resulted in the patient's death, despite the use of aggressive chemotherapy.


Assuntos
Tratamento Farmacológico , Extremidades , Linfoma , Linfoma não Hodgkin , Linfoma Anaplásico Cutâneo Primário de Células Grandes , Prognóstico , Pele , Taxa de Sobrevida
5.
Korean Journal of Medicine ; : 224-230, 2015.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-167629

RESUMO

Primary esophageal lymphoma is very rare, and most reported cases are histologically mucosa-associated lymphoid tissue lymphoma. Therefore, the principle treatment strategy for primary esophageal lymphoma focuses on local treatments, such as endoscopic mucosal resection or radiation therapy, but systemic chemotherapy plays the central role in the treatment of diffuse large B cell lymphoma (DLBCL). Generally, standard treatment for DLBCL is six or three cycles of R-CHOP chemotherapy followed by involved field radiation therapy according to stage. However, the optimal treatment strategy for primary esophageal DLBCL, and the role of additional radiation is not settled, due to a paucity of cases. Moreover, the clinical characteristics related to the etiology and natural course are also unknown. Here, we present two cases of primary esophageal DLBCL with a literature review.


Assuntos
Tratamento Farmacológico , Esôfago , Linfoma , Linfoma de Células B , Linfoma de Zona Marginal Tipo Células B , Linfoma Difuso de Grandes Células B
6.
Blood Research ; : 6-6, 2015.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-203508

RESUMO

No abstract available.


Assuntos
Hemorragia , Púrpura Trombocitopênica Idiopática
7.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-76675

RESUMO

BACKGROUND/AIMS: Among diffuse large B cell lymphoma (DLBCL) patients, determining the appropriate dose and chemotherapy schedule to balance toxicity and efficacy is harder in elderly than in younger patients. Moreover, there are no currently available clinical factors that consistently identify patients who are unfit to receive chemotherapy. Therefore, the clinical characteristics and outcomes of elderly patients with DLBCL and the causes of treatment-related death were investigated in this study. METHODS: The clinical characteristics and outcomes of 44 elderly (> or = 70 years of age) patients diagnosed with DLBCL between January 2005 and June 2013 were evaluated. Variable clinical data along with the response rate, overall survival (OS), and causes of treatment-related death or treatment interruption were investigated. RESULTS: The median OS was 18.6 months, and 19 patients completed curative treatment. The mean average relative dose intensity of adriamycin in patients who completed chemotherapy was 0.617, and of these patients, 16 achieved complete remission. Chemotherapy incompletion, infectious complications, ex tranoda l involvement, high lactate dehydrogenase, poor performance status, and low albumin level at diagnosis were related to a shorter OS. However, multivariate analysis revealed that only infections and chemotherapy incompletion were significantly related to poor prognosis. The most common cause of treatment-related death was infection, and patients who had experienced infectious complications tended to have lower albumin levels than those of patients without such complications. CONCLUSIONS: In the treatment of elderly lymphoma patients, the dose intensity of adriamycin is not as important as it is in young patients. However, in elderly patients, infections are particularly dangerous, especially in patients with low albumin levels.


Assuntos
Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Fatores Etários , Antibióticos Antineoplásicos/administração & dosagem , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Distribuição de Qui-Quadrado , Doenças Transmissíveis/sangue , Progressão da Doença , Doxorrubicina/administração & dosagem , Avaliação Geriátrica , Estimativa de Kaplan-Meier , Linfoma Difuso de Grandes Células B/sangue , Análise Multivariada , Modelos de Riscos Proporcionais , Indução de Remissão , República da Coreia , Estudos Retrospectivos , Fatores de Risco , Albumina Sérica/análise , Fatores de Tempo , Resultado do Tratamento
8.
Korean Journal of Medicine ; : 101-105, 2015.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-106147

RESUMO

Sunitinib is a multi-target tyrosine kinase inhibitor used to treat gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. The most common adverse reactions are known to be nausea, fatigue, diarrhea, stomatitis, esophagitis, hypertension, skin toxicity (hand-foot syndrome), hypothyroidism, and reduction in the cardiac output of the left ventricle. Herein, we report the case of a 57 year-old female who visited our hospital complaining of epigastric pain. She had been taking sunitinib at 25 mg/day to treat a metastatic pancreatic neuroendocrine tumor. Upon computed tomography performed on admission, we observed that fluid had collected around the pancreas. Laboratory analysis revealed hypertriglyceridemia (triglycerides 993 mg/dL). Tyrosine kinase inhibitors are known to have limited effects on lipid metabolism. In this case, we suggest that hyperglycemia seems to have had a limited effect on lipid levels. We are rather of the view that hyperglycemia, a history of distal pancreatectomy, and hypothyrodisim, indirectly caused the observed hypertriglyceridemia.


Assuntos
Feminino , Humanos , Carcinoma de Células Renais , Débito Cardíaco , Diarreia , Esofagite , Fadiga , Tumores do Estroma Gastrointestinal , Ventrículos do Coração , Hiperglicemia , Hipertensão , Hipertrigliceridemia , Hipotireoidismo , Metabolismo dos Lipídeos , Náusea , Tumores Neuroendócrinos , Pâncreas , Pancreatectomia , Proteínas Tirosina Quinases , Pele , Estomatite
10.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-106239

RESUMO

Development of tumor lysis syndrome (TLS) may occur after chemotherapy or spontaneously in bulky or rapidly growing tumors. This syndrome is frequent but preventable in patients with hematologic malignancies. TLS following therapy has been reported infrequently in various types of solid tumors. TLS associated with oxaliplatin containing chemotherapy in a solid tumor has never been reported. A 59-year-old man received 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) chemotherapy for metastatic colon cancer. Development of TLS occurred three days after administration of chemotherapy. Two days later, his abnormal laboratory findings were recovered with appropriate management. To the best of our knowledge, the current case is the first report on development of acute TLS following oxaliplatin containing chemotherapy in a patient with colon cancer. We also review the literature on tumor lysis syndrome in patients with colorectal cancer.


Assuntos
Humanos , Pessoa de Meia-Idade , Colo , Neoplasias do Colo , Neoplasias Colorretais , Tratamento Farmacológico , Fluoruracila , Neoplasias Hematológicas , Leucovorina , Síndrome de Lise Tumoral
12.
Korean Journal of Medicine ; : 641-646, 2014.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-151948

RESUMO

Primary mediastinal choriocarcinoma is an extremely rare extragonadal germ cell malignancy. A 58-year-old male presented with a lung mass, which was incidentally discovered during a periodic medical checkup. Percutaneous needle biopsy showed poorly differentiated carcinoma with large pleomorphic morphology. After the patient underwent right upper lobectomy and lymphadenectomy, the final diagnosis was choriocarcinoma. The patient received four sequential cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin). After completion of BEP chemotherapy, follow-up positron emission tomography (PET) showed a complete metabolic response. Although the mediastinum is one of the most common primary sites of extragonadal germ cell tumors, primary mediastinal choriocarcinoma is liable to be misdiagnosed as lung cancer or Hodgkin lymphoma. Notably, large cell carcinoma of the lung can be confused with choriocarcinoma even after percutaneous needle biopsy. We report a case of primary mediastinal choriocarcinoma mimicking large cell carcinoma of the lung in a male patient in his 50s.


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Gravidez , Biópsia por Agulha , Carcinoma de Células Grandes , Coriocarcinoma , Diagnóstico , Tratamento Farmacológico , Etoposídeo , Seguimentos , Células Germinativas , Doença de Hodgkin , Neoplasias Pulmonares , Pulmão , Excisão de Linfonodo , Mediastino , Neoplasias Embrionárias de Células Germinativas , Tomografia por Emissão de Pósitrons
13.
Korean Journal of Medicine ; : 357-362, 2014.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-63185

RESUMO

Rituximab, an anti-CD20 monoclonal antibody, is an effective target agent against the B lymphocytes in B-cell lymphoid malignancies and various lymphoproliferative diseases. Moreover, the toxicity of rituximab is less severe than that of conventional cytotoxic agents, which has promoted the widespread application of rituximab in the treatment of B-cell lymphoma. However, depletion of B lymphocytes by rituximab, which leads to secondary hypogammaglobulinemia, can cause deterioration of humoral immunity. Although immune reconstitution after hematopoietic stem cell transplantation is known to prevent prolonged hypogammaglobulinemia, very few cases of long-standing hypogammaglobulinemia have been reported. We report herein a case of prolonged hypogammaglobulinemia after rituximab-containing chemotherapy and splenectomy in a patient with non-Hodgkin's lymphoma and discuss the clinical significance and pathogenetic mechanism of this phenomenon with a literature review.


Assuntos
Humanos , Agamaglobulinemia , Linfócitos B , Citotoxinas , Tratamento Farmacológico , Transplante de Células-Tronco Hematopoéticas , Deficiência de IgG , Imunidade Humoral , Linfoma , Linfoma de Células B , Linfoma não Hodgkin , Esplenectomia , Rituximab
14.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-113909

RESUMO

In the article cited above, Fig. 3 was input incorrectly.

15.
Radiation Oncology Journal ; : 206-215, 2013.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-115566

RESUMO

PURPOSE: Re-irradiation (re-RT) is considered a treatment option for inoperable locoregionally recurrent head and neck cancer (HNC) after prior radiotherapy. We evaluated the efficacy and safety of re-RT using Helical Tomotherapy as image-guided intensity-modulated radiotherapy in recurrent HNC. MATERIALS AND METHODS: Patients diagnosed with recurrent HNC and received re-RT were retrospectively reviewed. Primary endpoint was overall survival (OS) and secondary endpoints were locoregional control and toxicities. RESULTS: The median follow-up period of total 9 patients was 18.7 months (range, 4.1 to 76 months) and that of 3 alive patients was 49 months (range, 47 to 76 months). Median dose of first radiotherapy and re-RT was 64.8 and 47.5 Gy10. Median cumulative dose of the two courses of radiotherapy was 116.3 Gy10 (range, 91.8 to 128.9 Gy10) while the median interval between the two courses of radiation was 25 months (range, 4 to 137 months). The response rate after re-RT of the evaluated 8 patients was 75% (complete response, 4; partial response, 2). Median locoregional relapse-free survival after re-RT was 11.9 months (range, 3.4 to 75.1 months) and 5 patients eventually presented with treatment failure (in-field failure, 2; in- and out-field failure, 2; out-field failure, 1). Median OS of the 8 patients was 20.3 months (range, 4.1 to 75.1 months). One- and two-year OS rates were 62.5% and 50%, respectively. Grade 3 leucopenia developed in one patient as acute toxicity, and grade 2 osteonecrosis and trismus as chronic toxicity in another patient. CONCLUSION: Re-RT using Helical Tomotherapy for previously irradiated patients with unresectable locoregionally recurrent HNC may be a feasible treatment option with long-term survival and acceptable toxicities.


Assuntos
Humanos , Seguimentos , Neoplasias de Cabeça e Pescoço , Cabeça , Osteonecrose , Radioterapia , Radioterapia Guiada por Imagem , Radioterapia de Intensidade Modulada , Estudos Retrospectivos , Falha de Tratamento , Trismo
16.
Korean Journal of Medicine ; : 602-607, 2013.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-80226

RESUMO

Wernicke's encephalopathy (WE) is an acute neuropsychiatric syndrome resulting from thiamine deficiency. Traditionally, diagnosis of WE rests on a clinical symptom triad consisting of ocular signs, altered consciousness, and ataxia. However, the complete triad is only present in a fraction of cases, which means that WE tends to be under-diagnosed, especially in nonalcoholic patients. Brain MRI of WE patients usually shows symmetrical signal intensity alterations in the thalami, mammillary bodies, and periaqueductal area, because of cytotoxic edema in the same region. These typical findings are useful diagnostic leads in WE patients with atypical symptoms. However, atypical findings can occasionally be seen in the vermis of cerebellum and cerebellar nuclei. Notably, alterations of signal intensity in the cerebellar dentate nuclei, which is a typical finding of metronidazole-induced encephalopathy (MIE), need to be distinguished according to medication history and response to thiamine.


Assuntos
Humanos , Ataxia , Encéfalo , Núcleos Cerebelares , Cerebelo , Estado de Consciência , Edema , Corpos Mamilares , Metronidazol , Tiamina , Deficiência de Tiamina , Encefalopatia de Wernicke
17.
Korean Journal of Medicine ; : 308-312, 2013.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-34181

RESUMO

The lymphoproliferative disease multiple myeloma and the myeloproliferative disease polycythemia vera have different pathogenic mechanisms and different natural courses. Thus, the concomitant development of these two diseases in the same individual is rare. In most previously reported cases of both diseases, one disease was assumed to be a secondary malignancy caused by chemotherapy for the other primary disease. Our case was diagnosed as smoldering myeloma based on increased bone marrow plasma cell numbers and monoclonal gammopathy during a regular follow-up visit for JAK2V617F mutation-positive polycythemia vera, which had not been treated except with phlebotomy. This case provides useful clues for understanding the pathogenesis of these two hematological malignancies and the association between them. Here, we report a case of polycythemia vera with a JAK2V617F mutation combined with smoldering myeloma and discuss the clinical significance and pathogenic association between these disorders of different lineages, along with a literature review.


Assuntos
Medula Óssea , Seguimentos , Neoplasias Hematológicas , Mieloma Múltiplo , Paraproteinemias , Flebotomia , Plasmócitos , Policitemia , Policitemia Vera
18.
19.
Korean Journal of Medicine ; : 507-511, 2012.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-741081

RESUMO

Hyperamylasemia in patients with lung cancer is relatively rare, occurring in 1-3% of all cases of the disease. The pathogenesis of hyperamylasemia in solid cancers is not clear. In Korea, no cases of hyperamylasemia have been reported in patients with adenocarcinoma of the lung. Instead, the lung cancers in patients with hyperamylasemia have in most cases been adenocarcinomas. We report a case of a 64-year-old woman with hyperamylasemia that was suspected to have been induced by mucinous adenocarcinoma of the lung. The patient's amylase isoenzyme pattern was of the salivary type. Systemic chemotherapy normalized her serum amylase levels and produced a partial response in her lung cancer.


Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Adenocarcinoma , Adenocarcinoma Mucinoso , Amilases , Hiperamilassemia , Coreia (Geográfico) , Pulmão , Neoplasias Pulmonares
20.
Korean Journal of Medicine ; : 507-511, 2012.
Artigo em Coreano | WPRIM (Pacífico Ocidental) | ID: wpr-21297

RESUMO

Hyperamylasemia in patients with lung cancer is relatively rare, occurring in 1-3% of all cases of the disease. The pathogenesis of hyperamylasemia in solid cancers is not clear. In Korea, no cases of hyperamylasemia have been reported in patients with adenocarcinoma of the lung. Instead, the lung cancers in patients with hyperamylasemia have in most cases been adenocarcinomas. We report a case of a 64-year-old woman with hyperamylasemia that was suspected to have been induced by mucinous adenocarcinoma of the lung. The patient's amylase isoenzyme pattern was of the salivary type. Systemic chemotherapy normalized her serum amylase levels and produced a partial response in her lung cancer.


Assuntos
Feminino , Humanos , Pessoa de Meia-Idade , Adenocarcinoma , Adenocarcinoma Mucinoso , Amilases , Hiperamilassemia , Coreia (Geográfico) , Pulmão , Neoplasias Pulmonares
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...